THC for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

THC for Health & Longevity

Created on 07/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Acts on a natural body signaling system that helps regulate pain, mood, appetite, and memory. Best-supported uses are modest: small relief of long-lasting pain, easing nausea and appetite loss during illness, and faster sleep onset that fades. The brain-aging promise rests on animal data only. Known harms — mental illness, dependence, accidents, heart events — currently outweigh unproven longevity benefits. (Full Review)

Protocol

Starting Dose
2.5 mg oral
Dronabinol once or twice daily, titrated to effect
Best Time
Evening
Sedation and psychomotor effects; daytime use generally avoided
Dosing Pattern
Split low doses
Tracks the short subjective duration better than one large dose
Time to effect
Inhaled
Minutes
Peaks around 30 minutes
Oral / Edible
30 min–2 hrs
Delayed onset; peaks later
Sleep Benefit
Fades 1–2 wks
Tolerance to the sleep effect develops within days to weeks

Benefits

Contraindications
  • Personal or family history of psychosis, schizophrenia, or bipolar disorder
  • Pregnancy or breastfeeding
  • Adolescents and young adults
  • Recent cardiovascular events (heart attack or stroke within ~90 days), unstable angina, or serious arrhythmia
  • Severe liver impairment
    •
Key Interactions
  • CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) raise THC; inducers (rifampin, carbamazepine, St. John's wort) lower it
  • CNS depressants (benzodiazepines, opioids, alcohol)
  • Sedating antihistamines (diphenhydramine)
  • Sedating supplements (melatonin, valerian, kava)
  • CBD and grapefruit raise THC exposure
  • Psychiatric medications and antiepileptics
    •

Risk & Side Effects

  • High: Psychosis and schizophrenia risk; cannabis use disorder and dependence; acute cognitive and psychomotor impairment
    •
  • Medium: Cardiovascular events; cannabinoid hyperemesis syndrome; anxiety, panic, and paranoia
    •
  • Low: Respiratory harm; withdrawal syndrome; chronic cognitive decline
    •
  • Speculative: Accelerated biological aging; reproductive and hormonal effects
    •

Monitoring

Marker Target Why
Resting Heart Rate 50–70 bpm THC acutely raises heart rate; a rising resting rate flags cardiovascular strain
Blood Pressure <120/80 mmHg Screens cardiovascular risk before use and detects acute changes
ALT / AST ALT <25 U/L (men), <20 (women) Confirms clearance capacity when co-medications are liver-metabolized
Fasting hs-CRP <1.0 mg/L Tracks systemic inflammation, relevant to both inflammation and cardiovascular risk

Cadence: Reassess 2–4 weeks after starting or changing dose, then every 3–6 months during continued use

Qualitative Assessment

  • Sleep quality and morning grogginess
  • Mood, anxiety level, and any unusual or paranoid thinking
  • Cognitive clarity, memory, and daytime focus
  • Appetite and any nausea
  • Craving, escalating use, or difficulty cutting back
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.